Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.37 |
| ▸ | CA2 | P00918 | 6/20 | 0.37 |
| ▸ | CA12 | O43570 | 5/20 | 0.37 |
| ▸ | CA9 | Q16790 | 5/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL51396 | 0.77 | NPSR1 (0.57) | CA1CA2CA12CA9CA14 | |
| SCHEMBL25588835 | 0.74 | CA12 (0.32) | CA1CA12CA14NPSR1CYP4F2 | |
| SCHEMBL26143735 | 0.73 | CA1 (0.38) | CA1CA2CA12CA9CA14 | |
| SCHEMBL2312894 | 0.70 | MAPK1 (0.34) | CA1CA2CA12CA9CA14 | |
| SCHEMBL21393556 | 0.68 | ALDH1A1 (0.34) | NPSR1 | |
| SCHEMBL10004931 | 0.67 | MAPK1 (0.35) | CYP4F2CYP4A11 | |
| SCHEMBL10835890 | 0.67 | USP2 (0.33) | CYP4F2CYP4A11 | |
| SCHEMBL3295142 | 0.67 | MAPK1 (0.33) | NPSR1CYP4F2CYP4A11 | |
| SCHEMBL20699067 | 0.67 | CA1 (0.36) | CA1CA2CA12CA9CA14 | |
| SCHEMBL4499031 | 0.67 | MAPK1 (0.33) | CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910378-B1 | HEPATITIS C INHIBITOR PEPTIDE ANALOGS | BOEHRINGER INGELHEIM INT (DE) | 2012-06-20 | — | — | EP | disclosed |
| EP-1771453-B1 | HEPATITIS C INHIBITOR DIPEPTIDE ANALOGS | BOEHRINGER INGELHEIM INT (DE) | 2012-05-30 | — | — | EP | disclosed |
| US-20120094897-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| WO-2012037259-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| EP-1771454-B1 | HEPATITIS C INHIBITOR PEPTIDE ANALOGS | BOEHRINGER INGELHEIM INT (DE) | 2011-06-15 | — | — | EP | disclosed |
| US-20110082182-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| EP-1673385-B1 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | BOEHRINGER INGELHEIM INT (DE) | 2011-03-02 | — | — | EP | disclosed |
| US-7767818-B2 | Hepatitis C inhibitor dipeptide analogs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-03 | — | — | US | disclosed |
| US-7696242-B2 | Hepatitis C inhibitor peptide analogs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-13 | — | — | US | disclosed |
| US-20100087382-A1 | Inhibitors of Hepatitis C NS3 Protease | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-08 | — | — | US | disclosed |
| US-20100028300-A1 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-04 | — | — | US | disclosed |
| US-7642235-B2 | Macrocyclic peptides active against the hepatitis C virus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-05 | — | — | US | disclosed |
| US-20090156822-A1 | Hepatitis C Inhibitor Dipeptide Analogs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-18 | — | — | US | disclosed |
| US-7511157-B2 | racemic mixtures, stereoisomers or optical isomers, useful as protease inhibitors; viricides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-31 | — | — | US | disclosed |
| US-20080200497-A1 | Hepatitis C Inhibitor Peptide Analogs | BAILEY MURRAY D | 2008-08-21 | — | — | US | disclosed |
| CN-1856502-A | Macrocyclic peptides active against hepatitis C virus | BOEHRINGER INGELHEIM INT (DE) | 2006-11-01 | — | — | CN | disclosed |
| US-20060046965-A1 | Hepatitis C inhibitor dipeptide analogs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-03-02 | — | — | US | disclosed |
| US-20060019905-A1 | inhibitors of the hepatitis C virus NS3 protease; azalactone intermediate reacted with cycloalkylsulfonamide and decylization; urea or carbamate-terminated alkylglycine, hydroxyproline, cyclopropylglycine tripeptide | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-01-26 | — | — | US | disclosed |
| US-20050080005-A1 | Macrocyclic peptides active against the hepatitis C virus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087382-A1 | Inhibitors of Hepatitis C NS3 Protease | RNASE1, GTF3C3, CTRL | CA1 4225/4885CA2 4322/4885CA12 4614/4885 |
| US-20090156822-A1 | Hepatitis C Inhibitor Dipeptide Analogs | DPP3, CTSC, ANPEP | CA1 3700/4885CA2 4543/4885CA12 3518/4885 |
| US-20120094897-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HDGF | CA1 4721/4885CA2 4249/4885CA12 4423/4885 |
| US-20060046965-A1 | Hepatitis C inhibitor dipeptide analogs | DPP3, CTSC, ANPEP | CA1 3700/4885CA2 4543/4885CA12 3518/4885 |
| US-20110082182-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | SARS1, VIP, MAVS | CA1 4316/4885CA2 4291/4885CA12 3218/4885 |
| US-20100028300-A1 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | CTRL, RPP30, RNASE1 | CA1 3041/4885CA2 3761/4885CA12 2763/4885 |
| US-20060019905-A1 | inhibitors of the hepatitis C virus NS3 protease; azalactone intermediate reacted with cycloalkylsulfonamide and decylization; urea or carbamate-terminated alkylglycine, hydroxyproline, cyclopropylglycine tripeptide | CPN1, HPN, CTSC | CA1 2282/4885CA2 3158/4885CA12 2553/4885 |
| US-20080200497-A1 | Hepatitis C Inhibitor Peptide Analogs | HAVCR2, ZC3HAV1, CTSC | CA1 3294/4885CA2 4559/4885CA12 3304/4885 |
| US-20050080005-A1 | Macrocyclic peptides active against the hepatitis C virus | CTRL, RPP30, RNASE1 | CA1 3041/4885CA2 3761/4885CA12 2763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.